SVB Securities Adjusts Pardes Biosciences' Price Target to $9 From $12, Keeps Outperform Rating
10:45 AM EST, 01/27/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Pardes Biosciences (NASDAQ:PRDS) PT Lowered to $9.00
Pardes Biosciences (NASDAQ:PRDS – Get Rating) had its price objective dropped by investment analysts at SVB Leerink from $12.00 to $9.00 in a research report issued on Friday, Benzinga reports. The
Pardes Biosciences Price Target Cut to $9.00/Share From $12.00 by SVB Leerink
Pardes Biosciences Is Maintained at Outperform by SVB Leerink
SVB Leerink Maintains Outperform on Pardes Biosciences, Lowers Price Target to $9
SVB Leerink analyst Roanna Ruiz maintains Pardes Biosciences (NASDAQ:PRDS) with a Outperform and lowers the price target from $12 to $9.
(SPAC) Special Purpose Acquisition Investigation: SKIL, OPFI, OTMO, PRDS, Contact Shareholder Rights Law Firm Johnson Fistel
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies
Carver Biosciences Announces Appointment of Three Members to Its Scientific Advisory Board
Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will
(SPAC) Special Purpose Acquisition Investigation: KIND, OPFI, OTMO, PRDS, Contact Shareholder Rights Law Firm Johnson Fistel
SAN DIEGO, Jan. 14, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition companies
Pardes Biosciences Files $200M Mixed Securities Shelf
Pardes Biosciences (NASDAQ:PRDS) Coverage Initiated by Analysts at JMP Securities
JMP Securities initiated coverage on shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a market outperform ra
Loading...
No Stock Yet